| Feature area | APH1A-specific finding | Evidence/details | Main implications | Key citation(s) |
|---|---|---|---|---|
| Identity verified | APH1A is the human **gamma-secretase subunit APH-1A** (Anterior pharynx-defective 1A), one of the two human APH-1 isoforms in the heterotetrameric gamma-secretase complex | Recent reviews and structural papers consistently describe four human gamma-secretase complexes generated by combinations of **PSEN1/2** with **APH1A/B**, plus NCSTN and PSENEN/PEN-2 | Confirms the target is the human gamma-secretase scaffold subunit, not an unrelated gene symbol | (pqac-00000000, pqac-00000004, pqac-00000008) |
| Molecular class / primary role | APH1A is a **non-catalytic, multi-pass membrane scaffold/stabilizer** required for assembly and maturation of gamma-secretase | APH-1 is described as stabilizing the enzyme complex and serving as a scaffold for assembly; presenilin only becomes active after incorporation into the full complex | APH1A does not catalyze peptide bond hydrolysis itself; instead it enables formation and function of the active protease complex | (pqac-00000008, pqac-00000009) |
| Membrane topology | APH1A is a **7-transmembrane-domain** protein | Sequence/topology summaries in recent reviews assign APH-1 seven TMDs, with **N-terminus facing the extracellular/luminal side** and **C-terminus facing cytosol** | Topology is consistent with a structural role in the membrane-embedded core of gamma-secretase | (pqac-00000008, pqac-00000005) |
| Key structural interfaces | APH1A forms a major membrane-embedded interface with presenilin involving APH-1 **TM2-TM4** contacting **PSEN1 TM1 and TM8-TM9**, with insertion of the PSEN1 C-terminus into the APH-1 helical bundle on the extracellular side | The 2024 cryo-EM APH-1B study defines the conserved PSEN1/APH-1 interface and shows that isoform-specific APH-1 regions contact PSEN1 across an interface of ~2000 Ų; these data are informative for APH1A because the APH1A-bound complex is the comparison reference | Provides a structural basis for APH1A as the presenilin-stabilizing factor and as a regulator of presenilin conformational dynamics | (pqac-00000001, pqac-00000005, pqac-00000015) |
| Isoform-specific structural determinants | Relative to APH-1B, APH-1A differs in **three non-conserved structural regions**, including the **TM3-TM4 loop**, which is implicated in substrate-induced conformational coupling | The 2024 cryo-EM comparison shows APH-1 isoform divergence clusters in specific regions and that substrate binding propagates conformational change toward the PSEN1/APH-1 interface | Supports the idea that APH1A is not just passive scaffold but helps tune gamma-secretase conformational states and product profiles | (pqac-00000000, pqac-00000005, pqac-00000015) |
| Complex assembly step 1 | **Nicastrin (NCSTN) and APH1A** first form an early subcomplex in the **endoplasmic reticulum** | Multiple reviews describe stepwise assembly beginning with NCSTN-APH-1 association in ER membranes | APH1A nucleates early assembly of gamma-secretase biogenesis | (pqac-00000004, pqac-00000008, pqac-00000009) |
| Complex assembly step 2 | The **NCSTN-APH1A subcomplex recruits full-length presenilin** | Presenilin joins the APH-1/NCT subcomplex before PEN-2 addition | Explains the historical alias “presenilin-stabilization factor” and APH1A’s central role in presenilin maturation | (pqac-00000008, pqac-00000009) |
| Complex assembly step 3 | **PEN-2/PSENEN** then binds, especially via **PSEN1 TMD4**, triggering presenilin autoproteolysis into NTF and CTF | Reviews summarize PEN-2-dependent activation after APH-1/NCT/presenilin preassembly | APH1A supports formation of the proenzyme whose maturation yields the active gamma-secretase complex | (pqac-00000008, pqac-00000004) |
| Post-assembly maturation | Full complex matures in the **Golgi**, where **nicastrin becomes fully glycosylated**, before onward trafficking | Recent review summarizes ER dimer formation and Golgi completion/maturation | Places APH1A function in the secretory pathway during biogenesis as well as later in active complexes | (pqac-00000004, pqac-00000008) |
| Contribution to catalysis | APH1A is **not the catalytic subunit**; catalysis occurs at **PSEN1 Asp257/Asp385** within the active site | Structural reviews place the catalytic aspartates in PSEN TM6 and TM7, with APH-1 acting as a supporting subunit | APH1A affects proteolysis indirectly through complex architecture, substrate gating, and stabilization | (pqac-00000008, pqac-00000010) |
| Contribution to substrate processing | APH-1 isoforms modulate **substrate processivity** and the **length distribution of Aβ peptides** produced from APP | 2024 structural work and recent reviews note that complexes containing **PSEN2 and/or APH-1B** generate relatively more long, aggregation-prone Aβ species than complexes with **PSEN1 and/or APH-1A** | By inference, APH1A-containing complexes are associated with comparatively greater processive trimming toward shorter Aβ products | (pqac-00000000, pqac-00000019) |
| Allosteric regulation | APH1A likely contributes to **allosteric-like coupling** between substrate binding and conformational changes in presenilin | The 2024 cryo-EM APH-1B/Aβ46 study shows substrate-induced rearrangements at the PSEN1/APH-1 interface and proposes an allosteric pathway connecting PSEN1 TM1/TM8-9 to the APH-1 TM3-TM4 loop; APH1A is the key comparator in these analyses | Strongest recent mechanistic evidence that APH1A-family proteins modulate gamma-secretase activity beyond simple assembly | (pqac-00000000, pqac-00000015) |
| Substrate class | Gamma-secretase complexes containing APH1A cleave **type I transmembrane proteins**, typically after ectodomain shedding and when the residual ectodomain is short | Recent reviews emphasize lack of strict sequence consensus but a common requirement for type I membrane topology and short ectodomains | Defines the biochemical context in which APH1A functions | (pqac-00000000, pqac-00000006, pqac-00000017) |
| APP processing pathway | In APP processing, gamma-secretase first performs **epsilon cleavage** near the cytosolic leaflet to release **AICD**, then sequentially trims membrane-retained Aβ intermediates to shorter Aβ species | Recent reviews summarize the Aβ49→46→43→40→37 and Aβ48→45→42→38 trimming lines | APH1A’s functional importance lies in shaping processivity of this sequential intramembrane trimming reaction | (pqac-00000010, pqac-00000011, pqac-00000014) |
| Notch pathway role | Gamma-secretase containing APH1A cleaves **Notch** after ADAM-mediated S2 cleavage, releasing **NICD** into the cytosol/nucleus | Notch is one of the best-established substrates and a central signaling readout of gamma-secretase function | Explains why APH1A loss has strong developmental consequences and why broad gamma-secretase inhibition causes Notch-related toxicity | (pqac-00000002, pqac-00000018) |
| Breadth of substrate proteome | Gamma-secretase processes **more than 145-150 substrates**; a 2023 unbiased microglial substrate screen identified **85 substrates**, including **59 not previously known** in that context | Hou et al. developed G-SECSI and showed extensive parallel processing in human microglia | APH1A participates in a broad regulated intramembrane proteolysis network rather than a single-pathway enzyme system | (pqac-00000006, pqac-00000016, pqac-00000017) |
| Subcellular localization of active function | APH1A functions in gamma-secretase complexes located in the **plasma membrane** and **endosomal system** after assembly in the ER/Golgi pathway | Reviews place mature complexes at the cell surface, endosomes, and lysosomes; super-resolution imaging confirms cell-surface gamma-secretase organization and dynamics | APH1A acts where membrane stubs of substrates encounter active gamma-secretase for intramembrane cleavage | (pqac-00000004, pqac-00000008) |
| Complex-specific trafficking context | Complexes containing **PSEN1** are recycled between the **cell surface and endosomes**, whereas **PSEN2** complexes are targeted more to **late endosomes/lysosomes** | De Strooper & Karran summarize compartmental differences among gamma-secretase complexes | APH1A localization depends partly on its presenilin partner; APH1A frequently participates in PSEN1 complexes with surface/endosomal activity | (pqac-00000004) |
| Disease relevance: development | **Aph1a knockout causes lethal Notch phenotypes during embryogenesis**, unlike the milder phenotype of Aph1b loss | Recent review contrasts knockout phenotypes of APH1 paralogs | Indicates APH1A is the more essential APH-1 paralog for canonical developmental Notch signaling | (pqac-00000004) |
| Disease relevance: Alzheimer’s disease | APH1A influences **Aβ peptide length distribution**, a core determinant of Alzheimer’s disease pathobiology, though AD-causing familial mutations are mainly in **PSEN1/2**, not APH1A | 2024 reviews emphasize that longer Aβ species seed aggregation; isoform composition of gamma-secretase contributes to Aβ-length bias | APH1A is mechanistically relevant to AD through complex composition and processivity, rather than as a common Mendelian AD mutation gene | (pqac-00000000, pqac-00000011, pqac-00000019) |
| Disease relevance: hidradenitis suppurativa and skin inflammation | Classical loss-of-function mutations in gamma-secretase subunits causing **hidradenitis suppurativa** have mostly been found in **NCSTN** and **PSENEN**, though recent dermatology reviews mention proposed APH1A/APH1B variants | Reviews distinguish AD-causing PSEN mutations from gamma-secretase haploinsufficiency syndromes affecting skin/Notch biology | Suggests APH1A may contribute to skin disease when gamma-secretase dosage/function is perturbed, but evidence is much weaker than for NCSTN/PSENEN | (pqac-00000004, pqac-00000009) |
| Disease relevance: pharmacology / oncology | Broad gamma-secretase inhibition causes mechanism-based toxicities, but selective targeting of specific complexes is an active therapeutic goal in **cancer** and **AD prevention** research | Recent reviews note first GSI approval (nirogacestat) and discuss the need for complex-selective inhibitors/modulators; some compounds show relative selectivity for APH1B- vs APH1A-containing complexes | APH1A is a practical pharmacology discriminator for designing safer, complex-selective gamma-secretase therapeutics | (pqac-00000003, pqac-00000019) |


*Table: This table compiles the main structural, mechanistic, localization, and disease-relevant features of human APH1A as a gamma-secretase subunit. It emphasizes recent cryo-EM and functional evidence, especially how APH1A supports assembly and modulates substrate processing.*